Global Duchenne Muscular Dystrophy Drugs Market Size, Status and Forecast 2024-2031

Report ID: 1013043 | Published Date: Jan 2025 | No. of Page: 109 | Base Year: 2024 | Rating: 4.3 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Molecular-based Therapies
        1.2.3 Steroid Therapy
        1.2.4 Other
    1.3 Market by Application
        1.3.1 Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Duchenne Muscular Dystrophy Drugs Market Perspective (2016-2027)
    2.2 Duchenne Muscular Dystrophy Drugs Growth Trends by Regions
        2.2.1 Duchenne Muscular Dystrophy Drugs Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Duchenne Muscular Dystrophy Drugs Historic Market Share by Regions (2016-2021)
        2.2.3 Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Regions (2022-2027)
    2.3 Duchenne Muscular Dystrophy Drugs Industry Dynamic
        2.3.1 Duchenne Muscular Dystrophy Drugs Market Trends
        2.3.2 Duchenne Muscular Dystrophy Drugs Market Drivers
        2.3.3 Duchenne Muscular Dystrophy Drugs Market Challenges
        2.3.4 Duchenne Muscular Dystrophy Drugs Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue
        3.1.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue (2016-2021)
        3.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Players (2016-2021)
    3.2 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Drugs Revenue
    3.4 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio
        3.4.1 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2020
    3.5 Duchenne Muscular Dystrophy Drugs Key Players Head office and Area Served
    3.6 Key Players Duchenne Muscular Dystrophy Drugs Product Solution and Service
    3.7 Date of Enter into Duchenne Muscular Dystrophy Drugs Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
    4.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Type (2016-2021)
    4.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2022-2027)

5 Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
    5.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Application (2016-2021)
    5.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Duchenne Muscular Dystrophy Drugs Market Size (2016-2027)
    6.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Type
        6.2.1 North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021)
        6.2.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027)
        6.2.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2027)
    6.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Application
        6.3.1 North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021)
        6.3.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027)
        6.3.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2027)
    6.4 North America Duchenne Muscular Dystrophy Drugs Market Size by Country
        6.4.1 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021)
        6.4.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Duchenne Muscular Dystrophy Drugs Market Size (2016-2027)
    7.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type
        7.2.1 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021)
        7.2.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027)
        7.2.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2027)
    7.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application
        7.3.1 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021)
        7.3.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027)
        7.3.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2027)
    7.4 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country
        7.4.1 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021)
        7.4.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size (2016-2027)
    8.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type
        8.2.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2027)
    8.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application
        8.3.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2027)
    8.4 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region
        8.4.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size (2016-2027)
    9.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type
        9.2.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021)
        9.2.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027)
        9.2.3 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2027)
    9.3 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application
        9.3.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021)
        9.3.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027)
        9.3.3 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2027)
    9.4 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country
        9.4.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021)
        9.4.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size (2016-2027)
    10.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type
        10.2.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2027)
    10.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application
        10.3.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2027)
    10.4 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country
        10.4.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Biogen
        11.1.1 Biogen Company Details
        11.1.2 Biogen Business Overview
        11.1.3 Biogen Duchenne Muscular Dystrophy Drugs Introduction
        11.1.4 Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.1.5 Biogen Recent Development
    11.2 Roche
        11.2.1 Roche Company Details
        11.2.2 Roche Business Overview
        11.2.3 Roche Duchenne Muscular Dystrophy Drugs Introduction
        11.2.4 Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.2.5 Roche Recent Development
    11.3 Daiichi Sankyo
        11.3.1 Daiichi Sankyo Company Details
        11.3.2 Daiichi Sankyo Business Overview
        11.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Introduction
        11.3.4 Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.3.5 Daiichi Sankyo Recent Development
    11.4 Pfizer
        11.4.1 Pfizer Company Details
        11.4.2 Pfizer Business Overview
        11.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Introduction
        11.4.4 Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.4.5 Pfizer Recent Development
    11.5 Cumberland Pharmaceuticals
        11.5.1 Cumberland Pharmaceuticals Company Details
        11.5.2 Cumberland Pharmaceuticals Business Overview
        11.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
        11.5.4 Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.5.5 Cumberland Pharmaceuticals Recent Development
    11.6 Santhera Pharmaceuticals
        11.6.1 Santhera Pharmaceuticals Company Details
        11.6.2 Santhera Pharmaceuticals Business Overview
        11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
        11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.6.5 Santhera Pharmaceuticals Recent Development
    11.7 Taiho Pharmaceutical
        11.7.1 Taiho Pharmaceutical Company Details
        11.7.2 Taiho Pharmaceutical Business Overview
        11.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Introduction
        11.7.4 Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.7.5 Taiho Pharmaceutical Recent Development
    11.8 Teijin Pharma
        11.8.1 Teijin Pharma Company Details
        11.8.2 Teijin Pharma Business Overview
        11.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Introduction
        11.8.4 Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.8.5 Teijin Pharma Recent Development
    11.9 Akashi Therapeutics
        11.9.1 Akashi Therapeutics Company Details
        11.9.2 Akashi Therapeutics Business Overview
        11.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
        11.9.4 Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.9.5 Akashi Therapeutics Recent Development
    11.10 Sarepta Therapeutics
        11.10.1 Sarepta Therapeutics Company Details
        11.10.2 Sarepta Therapeutics Business Overview
        11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
        11.10.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.10.5 Sarepta Therapeutics Recent Development
    11.11 BioMarin
        11.11.1 BioMarin Company Details
        11.11.2 BioMarin Business Overview
        11.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Introduction
        11.11.4 BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.11.5 BioMarin Recent Development
    11.12 Fibrogen Inc
        11.12.1 Fibrogen Inc Company Details
        11.12.2 Fibrogen Inc Business Overview
        11.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Introduction
        11.12.4 Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.12.5 Fibrogen Inc Recent Development
    11.13 Nobelpharma Co. Ltd
        11.13.1 Nobelpharma Co. Ltd Company Details
        11.13.2 Nobelpharma Co. Ltd Business Overview
        11.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Introduction
        11.13.4 Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.13.5 Nobelpharma Co. Ltd Recent Development
    11.14 Eloxx Pharmaceuticals
        11.14.1 Eloxx Pharmaceuticals Company Details
        11.14.2 Eloxx Pharmaceuticals Business Overview
        11.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
        11.14.4 Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
        11.14.5 Eloxx Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Molecular-based Therapies
    Table 3. Key Players of Steroid Therapy
    Table 4. Key Players of Other
    Table 5. Global Duchenne Muscular Dystrophy Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Duchenne Muscular Dystrophy Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Duchenne Muscular Dystrophy Drugs Market Size by Regions (2016-2021) & (US$ Million)
    Table 8. Global Duchenne Muscular Dystrophy Drugs Market Share by Regions (2016-2021)
    Table 9. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 10. Global Duchenne Muscular Dystrophy Drugs Market Share by Regions (2022-2027)
    Table 11. Duchenne Muscular Dystrophy Drugs Market Trends
    Table 12. Duchenne Muscular Dystrophy Drugs Market Drivers
    Table 13. Duchenne Muscular Dystrophy Drugs Market Challenges
    Table 14. Duchenne Muscular Dystrophy Drugs Market Restraints
    Table 15. Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2016-2021) & (US$ Million)
    Table 16. Global Duchenne Muscular Dystrophy Drugs Market Share by Players (2016-2021)
    Table 17. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2020)
    Table 18. Ranking of Global Top Duchenne Muscular Dystrophy Drugs Companies by Revenue (US$ Million) in 2020
    Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue (CR5 and HHI) & (2016-2021)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Duchenne Muscular Dystrophy Drugs Product Solution and Service
    Table 22. Date of Enter into Duchenne Muscular Dystrophy Drugs Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) (US$ Million)
    Table 25. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2016-2021)
    Table 26. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 27. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 28. Global Duchenne Muscular Dystrophy Drugs Market Size Share by Application (2016-2021) & (US$ Million)
    Table 29. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2016-2021)
    Table 30. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 31. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 32. North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) (US$ Million)
    Table 33. North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) & (US$ Million)
    Table 34. North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) (US$ Million)
    Table 35. North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) & (US$ Million)
    Table 36. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021) & (US$ Million) 
    Table 37. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027) & (US$ Million) 
    Table 38. Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) (US$ Million)
    Table 39. Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) & (US$ Million)
    Table 40. Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) (US$ Million)
    Table 41. Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) & (US$ Million)
    Table 42. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021) & (US$ Million) 
    Table 43. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027) & (US$ Million) 
    Table 44. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) (US$ Million)
    Table 45. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) & (US$ Million)
    Table 46. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) (US$ Million)
    Table 47. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) & (US$ Million)
    Table 48. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2016-2021) & (US$ Million) 
    Table 49. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2022-2027) & (US$ Million) 
    Table 50. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) (US$ Million)
    Table 51. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) & (US$ Million)
    Table 52. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) (US$ Million)
    Table 53. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) & (US$ Million)
    Table 54. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021) & (US$ Million) 
    Table 55. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027) & (US$ Million) 
    Table 56. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2016-2021) (US$ Million)
    Table 57. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2022-2027) & (US$ Million)
    Table 58. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2016-2021) (US$ Million)
    Table 59. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2022-2027) & (US$ Million)
    Table 60. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2016-2021) & (US$ Million) 
    Table 61. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2022-2027) & (US$ Million) 
    Table 62. Biogen Company Details
    Table 63. Biogen Business Overview
    Table 64. Biogen Duchenne Muscular Dystrophy Drugs Product
    Table 65. Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 66. Biogen Recent Development
    Table 67. Roche Company Details
    Table 68. Roche Business Overview
    Table 69. Roche Duchenne Muscular Dystrophy Drugs Product
    Table 70. Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 71. Roche Recent Development
    Table 72. Daiichi Sankyo Company Details
    Table 73. Daiichi Sankyo Business Overview
    Table 74. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product
    Table 75. Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 76. Daiichi Sankyo Recent Development
    Table 77. Pfizer Company Details
    Table 78. Pfizer Business Overview
    Table 79. Pfizer Duchenne Muscular Dystrophy Drugs Product
    Table 80. Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 81. Pfizer Recent Development
    Table 82. Cumberland Pharmaceuticals Company Details
    Table 83. Cumberland Pharmaceuticals Business Overview
    Table 84. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
    Table 85. Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 86. Cumberland Pharmaceuticals Recent Development
    Table 87. Santhera Pharmaceuticals Company Details
    Table 88. Santhera Pharmaceuticals Business Overview
    Table 89. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
    Table 90. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 91. Santhera Pharmaceuticals Recent Development
    Table 92. Taiho Pharmaceutical Company Details
    Table 93. Taiho Pharmaceutical Business Overview
    Table 94. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product
    Table 95. Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 96. Taiho Pharmaceutical Recent Development
    Table 97. Teijin Pharma Company Details
    Table 98. Teijin Pharma Business Overview
    Table 99. Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 100. Teijin Pharma Recent Development
    Table 101. Akashi Therapeutics Company Details
    Table 102. Akashi Therapeutics Business Overview
    Table 103. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product
    Table 104. Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 105. Akashi Therapeutics Recent Development
    Table 106. Sarepta Therapeutics Company Details
    Table 107. Sarepta Therapeutics Business Overview
    Table 108. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product
    Table 109. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 110. Sarepta Therapeutics Recent Development
    Table 111. BioMarin Company Details
    Table 112. BioMarin Business Overview
    Table 113. BioMarin Duchenne Muscular Dystrophy Drugs Product
    Table 114. BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 115. BioMarin Recent Development
    Table 116. Fibrogen Inc Company Details
    Table 117. Fibrogen Inc Business Overview
    Table 118. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product
    Table 119. Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 120. Fibrogen Inc Recent Development
    Table 121. Nobelpharma Co. Ltd Company Details
    Table 122. Nobelpharma Co. Ltd Business Overview
    Table 123. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product
    Table 124. Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 125. Nobelpharma Co. Ltd Recent Development
    Table 126. Eloxx Pharmaceuticals Company Details
    Table 127. Eloxx Pharmaceuticals Business Overview
    Table 128. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
    Table 129. Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2016-2021) & (US$ Million)
    Table 130. Eloxx Pharmaceuticals Recent Development
    Table 131. Research Programs/Design for This Report
    Table 132. Key Data Information from Secondary Sources
    Table 133. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Duchenne Muscular Dystrophy Drugs Market Share by Type: 2020 VS 2027
    Figure 2. Molecular-based Therapies Features
    Figure 3. Steroid Therapy Features
    Figure 4. Other Features
    Figure 5. Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2020 VS 2027
    Figure 6. Hospitals Case Studies
    Figure 7. Clinics Case Studies
    Figure 8. Others Case Studies
    Figure 9. Duchenne Muscular Dystrophy Drugs Report Years Considered
    Figure 10. Global Duchenne Muscular Dystrophy Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 11. Global Duchenne Muscular Dystrophy Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 12. Global Duchenne Muscular Dystrophy Drugs Market Share by Regions: 2020 VS 2027
    Figure 13. Global Duchenne Muscular Dystrophy Drugs Market Share by Regions (2022-2027)
    Figure 14. Global Duchenne Muscular Dystrophy Drugs Market Share by Players in 2020
    Figure 15. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2020
    Figure 16. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2020
    Figure 17. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2016-2021)
    Figure 18. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2022-2027)
    Figure 19. North America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 20. North America Duchenne Muscular Dystrophy Drugs Market Share by Type (2016-2027)
    Figure 21. North America Duchenne Muscular Dystrophy Drugs Market Share by Application (2016-2027)
    Figure 22. North America Duchenne Muscular Dystrophy Drugs Market Share by Country (2016-2027)
    Figure 23. United States Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Canada Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Duchenne Muscular Dystrophy Drugs Market Share by Type (2016-2027)
    Figure 27. Europe Duchenne Muscular Dystrophy Drugs Market Share by Application (2016-2027)
    Figure 28. Europe Duchenne Muscular Dystrophy Drugs Market Share by Country (2016-2027)
    Figure 29. Germany Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. France Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. U.K. Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Italy Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Russia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Nordic Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Type (2016-2027)
    Figure 37. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Application (2016-2027)
    Figure 38. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Region (2016-2027)
    Figure 39. China Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Japan Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. South Korea Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. India Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Australia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Type (2016-2027)
    Figure 47. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Application (2016-2027)
    Figure 48. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Country (2016-2027)
    Figure 49. Mexico Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Brazil Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Type (2016-2027)
    Figure 53. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Application (2016-2027)
    Figure 54. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Country (2016-2027)
    Figure 55. Turkey Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. UAE Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Biogen Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 59. Roche Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 60. Daiichi Sankyo Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 61. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 62. Cumberland Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 63. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 64. Taiho Pharmaceutical Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 65. Teijin Pharma Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 66. Akashi Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 67. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 68. BioMarin Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 69. Fibrogen Inc Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 70. Nobelpharma Co. Ltd Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 71. Eloxx Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2016-2021)
    Figure 72. Bottom-up and Top-down Approaches for This Report
    Figure 73. Data Triangulation
    Figure 74. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Biogen
Roche
Daiichi Sankyo
Pfizer
Cumberland Pharmaceuticals
Santhera Pharmaceuticals
Taiho Pharmaceutical
Teijin Pharma
Akashi Therapeutics
Sarepta Therapeutics
BioMarin
Fibrogen Inc
Nobelpharma Co. Ltd
Eloxx Pharmaceuticals
Frequently Asked Questions
Duchenne Muscular Dystrophy Drugs report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Duchenne Muscular Dystrophy Drugs report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Duchenne Muscular Dystrophy Drugs report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports